Skip to main content

Table 2 IPD and pneumonia incidence and mortality according to age and risk group

From: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

  

Incidence

Mortality

Age group

Risk group

Bacteraemia

Meningitis

Pneumonia with hospital contact

Pneumonia without hospital contact

General population

Bacteraemia

Meningitis

Pneumonia with hospital contact

Pneumonia without hospital contact

18–49 years

Low risk

1.6

0.2

82.5

509.4

0.07

20.98

5.26

0.11

0

At risk

10.4

2.5

661.3

1,200.5

0.22

1.81

0.00

0.65

0

High risk

10.4

2.5

2,560.6

1,200.5

0.49

2.34

0.00

1.90

0

50–64 years

Low risk

3.2

0.6

142.9

1,046.1

0.40

20.98

5.26

0.48

0

At risk

24.4

1.9

1,405.2

1,703.3

0.84

1.81

0.00

0.93

0

High risk

24.4

1.9

7,898.7

1,703.3

2.38

2.34

0.00

1.98

0

65–74 years

Low risk

6.5

0.0

294.2

1,326.9

1.32

16.81

15.38

1.36

0

At risk

46.6

2.6

2,814.3

3,296.6

1.96

25.00

32.00

2.44

0

High risk

46.6

2.6

33,604.9

3,296.6

4.65

28.27

11.76

2.07

0

75–84 years

Low risk

8.0

0.0

630.4

1,788.2

4.10

16.81

15.38

3.16

0

At risk

63.0

2.9

5,011.3

4,646.8

4.95

25.00

32.00

3.88

0

High risk

63.0

2.9

31,958.8

4,646.8

7.85

28.27

11.76

4.05

0

85–99 years

Low risk

16.7

0.0

1,322.0

1,773.1

18.73

16.81

15.38

8.94

0

At risk

98.9

0.0

10,795.0

6,895.2

14.93

25.00

32.00

11.14

0

High risk

98.9

0.0

39,285.7

6,895.2

15.07

28.27

11.76

19.80

0

  1. Note: The incidence of bacteraemia, meningitis and pneumonia is specified per 100,000 persons. The mortality in the general population is specified per 100 persons, whereas the mortality rates of bacteriaemia, meningitis and pneumonia are specified per 100 cases of disease. IPD: Invasive pneumococcal diseases. Sources: [21, 23, 25,26,27,28]